LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

25.82 -2.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.76

Максимум

26.03

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+20.35% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	881M 3.3B
Предишно отваряне	28.61
Предишно затваряне	25.82

Настроения в новините

By Acuity

50%

155 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.02.2026 г., 16:32 ч. UTC

Печалби

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13.02.2026 г., 21:57 ч. UTC

Печалби

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:20 ч. UTC

Печалби

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13.02.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Dollar Pares Down Early Losses -- Market Talk

13.02.2026 г., 20:39 ч. UTC

Пазарно говорене

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13.02.2026 г., 20:28 ч. UTC

Пазарно говорене

Oil Settles Week Lower -- Market Talk

13.02.2026 г., 19:51 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:29 ч. UTC

Печалби

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13.02.2026 г., 18:18 ч. UTC

Придобивния, сливания и поглъщания

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13.02.2026 г., 17:52 ч. UTC

Печалби

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13.02.2026 г., 17:16 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13.02.2026 г., 16:59 ч. UTC

Печалби

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13.02.2026 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13.02.2026 г., 16:11 ч. UTC

Печалби

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13.02.2026 г., 16:07 ч. UTC

Пазарно говорене

Hungarian Forint Could Rise Further -- Market Talk

13.02.2026 г., 15:54 ч. UTC

Печалби

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13.02.2026 г., 15:26 ч. UTC

Пазарно говорене

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13.02.2026 г., 15:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13.02.2026 г., 15:00 ч. UTC

Печалби

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13.02.2026 г., 14:50 ч. UTC

Пазарно говорене

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13.02.2026 г., 14:44 ч. UTC

Печалби

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13.02.2026 г., 14:22 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

13.02.2026 г., 14:21 ч. UTC

Пазарно говорене

Печалби

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13.02.2026 г., 14:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Move Lower -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

20.35% нагоре

12-месечна прогноза

Среден 32 USD 20.35%

Висок 37 USD

Нисък 30 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

155 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.